Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 549.04 +18.28 (3.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $530.76 | 52 Week High | $134.71 | |||
| Open | $535.63 | 52 Week Low | $73.31 | |||
| Day High | $550.77 | P/E | N/A | |||
| Day Low | $527.38 | EPS | $-1.98 | |||
| Volume | 1,810,310 | |||||
